Research and Clinical Trials

An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic RCC.
Brief Description  
The purpose of this study is to compare the safety and efficacy of the study drug RAD001 given before Sunitinib versus taking Sunitinib before the study drug, RAD001. The order for which Sunitinib and RAD001 are given is being investigated to determine the most effective way to slow tumor growth. Additionally, both drugs are being investigated to determine their harmful side effects in order to see which study treatment schedule has less side effects for the patient.
Who may be Eligible  
Patients with advanced renal cell carcinoma of either clear cell or non clear cell histology. Patients with or without nephrectomy. Patients with one measurable lesions per RECIST criteria. Patients with adequate left ventricular ejection fraction. Patients with stable CNS metastases for greater than or equal to 3 months prior to enrollment are permitted.
Genitourinary Cancer
IRB Number  
Principal Investigator  
Amin, Asim

For More Information, Contact  Melissa  R, Morrison
Phone:  (704) 355-7024  Fax:  (704) 355-1188  
Address:1025 Morehead Medical Drive Suite 600 Charlotte, NC 28204